Cellectis S.A 6-K, filed Aug 7, 2023

Cellectis S.A. (CLLS)

6-K 2023-08-07 For: 2023-08-07

View Original

Added on April 12, 2026

About this 6-K

Cellectis S.A filed this 6-K on August 7, 2023.

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →

Exhibit		Title

99.1		Press Release dated August 7, 2023

		Cellectis S.A.
		(Registrant)


Date: August 7, 2023		/s/ André Choulika
		André Choulika
		Chief Executive Officer


CELLECTIS S.A. STATEMENT OF CONSOLIDATED FINANCIAL POSITION (unaudited) ($ in thousands)

	As of
	December 31, 2022		June 30, 2023


ASSETS
Non-current assets
Intangible assets	718		695
Property, plant, and equipment	63,621		59,231
Right-of-use assets	44,275		41,457
Non-current financial assets	8,791		13,006
Total non-current assets	117,406		114,389

Current assets
Trade receivables	772		422
Subsidies receivables	14,496		19,488
Other current assets	9,078		7,869
Cash and cash equivalent and Current financial assets	97,697		85,505
Total current assets	122,043		113,285
Total assets held for sale	21,768		0
TOTAL ASSETS	261,216		227,674

LIABILITIES
Shareholders’ equity
Share capital	2,955		3,491
Premiums related to the share capital	583,122		476,224
Currency translation adjustment	(28,605	)	(37,050	)
Retained earnings	(333,365	)	(305,392	)
Net income (loss)	(106,139	)	(40,715	)
Total shareholders’ equity - Group Share	117,968		96,558
Non-controlling interests	7,973		0
Total shareholders’ equity	125,941		96,558

Non-current liabilities
Non-current financial liabilities	20,531		40,270
Non-current lease debts	49,358		46,157
Non-current provisions	2,390		2,641
Total non-current liabilities	72,279		89,068

Current liabilities
Current financial liabilities	5,088		5,185
Current lease debts	7,872		8,270
Trade payables	21,456		19,229
Deferred revenues and deferred income	59		241
Current provisions	477		1,029
Other current liabilities	13,179		8,093
Total current liabilities	48,131		42,047
Total liabilities related to asset held for sale	14,864		0
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	261,216		227,674


Cellectis S.A. UNAUDITED STATEMENTS OF CONSOLIDATED OPERATIONS For the three-month period ended June 30, 2023 $ in thousands, except per share amounts

	For the three-month period ended June 30,
	2022 *		2023

Revenues and other income
Revenues	1,307		178
Other income	1,416		1,823
Total revenues and other income	2,723		2,001
Operating expenses
Cost of revenue	(329	)	(55	)
Research and development expenses	(25,630	)	(22,144	)
Selling, general and administrative expenses	(4,830	)	(3,950	)
Other operating income (expenses)	753		490
Total operating expenses	(30,036	)	(25,660	)
Operating income (loss)	(27,313	)	(23,659	)
Financial gain (loss)	8,301		15,982
Income tax	0		(258	)
Income (loss) from continuing operations	(19,012	)	(7,935	)
Income (loss) from discontinued operations	(442	)	(5,647	)
Net income (loss)	(19,454	)	(13,583	)
Attributable to shareholders of Cellectis	(18,946	)	(10,648	)
Attributable to non-controlling interests	(506	)	(2,935	)

Basic net income (loss) attributable to shareholders of Cellectis per share ($/share)	(0.42	)	(0.19	)
Diluted net income (loss) attributable to shareholders of Cellectis per share ($/share)	(0.42	)	(0.19	)
Basic net income (loss) attributable to shareholders of Cellectis per share ($ /share) from discontinued operations	0.00		(0.05	)
Diluted net income (loss) attributable to shareholders of Cellectis per share ($ /share) from discontinued operations	0.00		(0.05	)


CELLECTIS S.A. UNAUDITED STATEMENTS OF CONSOLIDATED OPERATIONS For the six-month period ended June 30, 2023 $ in thousands, except per share amounts

	For the six-month period ended June 30,
	2022 *		2023

Revenues and other income
Revenues	2,972		317
Other income	3,551		5,242
Total revenues and other income	6,523		5,560
Operating expenses
Cost of revenue	(714	)	(389	)
Research and development expenses	(52,231	)	(43,225	)
Selling, general and administrative expenses	(10,893	)	(8,914	)
Other operating income (expenses)	774		(83	)
Total operating expenses	(63,064	)	(52,612	)
Operating income (loss)	(56,541	)	(47,053	)
Financial gain (loss)	9,213		11,580
Income tax	0		(258	)
Income (loss) from continuing operations	(47,328	)	(35,731	)
Income (loss) from discontinued operations	(6,883	)	(10,377	)
Net income (loss)	(54,211	)	(46.108	)
Attributable to shareholders of Cellectis	(50,858	)	(40,715	)
Attributable to non-controlling interests	(3,352	)	(5,393	)

Basic net income (loss) attributable to shareholders of Cellectis per share ($/share)	(1.12	)	(0.76	)
Diluted net income (loss) attributable to shareholders of Cellectis per share ($/share)	(1.12	)	(0.76	)
Basic net income (loss) attributable to shareholders of Cellectis per share ($ /share) from discontinued operations	(0.08	)	(0.09	)
Diluted net income (loss) attributable to shareholders of Cellectis per share ($ /share) from discontinued operations	(0.08	)	(0.09	)


CELLECTIS S.A. DETAILS OF KEY PERFORMANCE INDICATORS BY REPORTABLE SEGMENTS – For the three-month period ended June 30, 2023 (unaudited) - ($ in thousands)

	For the three-month period ended June 30, 2022						For the three-month period ended June 30, 2023
$ in thousands	Plants (discontinued operations)		Therapeutics		Total reportable segments		Plants (discontinued operations)		Therapeutics		Total reportable segments

External revenues	42		1,307		1,348		1		178		179
External other income	-		1,416		1,416		-		1,823		1,823
External revenues and other income	42		2,723		2,765		1		2,001		2,002
Cost of revenue	0		(329	)	(329	)	(63	)	(55	)	(118	)
Research and development expenses	(3,419	)	(25,630	)	(29,048	)	(1,322	)	(22,144	)	(23,467	)
Selling, general and administrative expenses	(3,585	)	(4,830	)	(8,415	)	(976	)	(3,950	)	(4,927	)
Other operating income and expenses	198		753		951		(1,074	)	490		(584	)
Total operating expenses	(6,806	)	(30,036	)	(36,842	)	(3,435	)	(25,660	)	(29,095	)
Operating income (loss) before tax	(6,764	)	(27,313	)	(34,077	)	(3,434	)	(23,659	)	(27,093	)
Financial gain (loss)	6,322		8,301		14,623		(2,213	)	15,982		13,769
Income tax	-		-		-		-		(258	)	(258	)
Net income (loss) from discontinued operations	(442	)			(442	)	(5,647	)			(5,647	)
Net income (loss)	(442	)	(19,012	)	(19,454	)	(5,647	)	(7,935	)	(13,583	)
Non controlling interests	506		-		506		(2,935	)	-		(2,935	)
Net income (loss) attributable to shareholders of Cellectis	64		(19,012	)	(18,946	)	(2,712	)	(7,935	)	(10,648	)
R&D non-cash stock-based expense attributable to shareholder of Cellectis	226		1,454		1,681		103		797		900
SG&A non-cash stock-based expense attributable to shareholder of Cellectis	447		557		1,003		326		849		1,174
Adjustment of share-based compensation attributable to shareholders of Cellectis	673		2,011		2,684		428		1,646		2,074
Adjusted net income (loss) attributable to shareholders of Cellectis	737		(17,001	)	(16,264	)	(2,284	)	(6,289	)	(8,573	)
Depreciation and amortization	(608	)	(4,500	)	(5,108	)	(12	)	(4,419	)	(4,431	)
Additions to tangible and intangible assets	308		870		1,178		21		311		332


RECONCILIATION OF IFRS TO NON-IFRS NET INCOME For the three-month period ended June 30, 2023 (unaudited) - ($ in thousands except per share data)

	For the three-month period ended June 30,
	2022 *		2023

Net income (loss) attributable to shareholders of Cellectis	(18,946	)	(10,648	)
Adjustment:
Non-cash stock-based compensation expense attributable to shareholders of Cellectis	2,684		2,074
Adjusted net income (loss) attributable to shareholders of Cellectis	(16,263	)	(8,574	)

Basic Adjusted net income (loss) attributable to shareholders of Cellectis ($/share)	(0.36	)	(0.15	)
Basic adjusted earnings from discontinued operations attributable to shareholders of Cellectis ($ /share)	0.00		(0.05	)

Weighted average number of outstanding shares, basic (units)	45,497,127		55,583,768

Diluted Adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (1)	(0.36	)	(0.15	)
Diluted Adjusted net income (loss) attributable to shareholders of Cellectis ($/share) from discontinued operations	0.02		(0.04	)

Weighted average number of outstanding shares, diluted (units)	45,497,127		55,583,768